Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity

Diabetes Mellitus, Type 1 Clinical Trial

— EDIA  

Official title:

Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01735123
• Other study ID #: 1DP3DK094338-01
• Status: Completed
• Phase: N/A
• First received: November 24, 2012
• Last updated: February 24, 2017
• Start date: January 2013
• Est. completion date: August 2016

Study information

• Verified date: February 2017
• Source: Helsinki University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed mechanistic formula feeding study sets out to identify the mechanism(s) by which an extensively hydrolyzed casein formula is able to protect children at risk for type 1 diabetes (T1D) from beta-cell autoimmunity.

Description:

Based on clinical and experimental observations the study will focus on defining the effects of two different formulas on intestinal permeability, IL (interleukin)-17 immunity, serum metabolome, and gut microflora. The study will be based on a randomized pilot intervention trial using an intention to treat statistical analysis to compare e.g. gut permeability between the two treatment groups. The investigators hypothesize that the extensively hydrolyzed casein formula decreases intestinal permeability, down-regulates IL-17 immunity and proinflammatory lysophosphatidylcholines, and stabilize Lactobacilli levels in the gut microflora when compared to the conventional cow's milk formula. The study population comprises 120 newborn infants with HLA(Human Leukocyte Antigen)-conferred susceptibility to T1D. The mothers will be encouraged to exclusively breast-feed their infants as long as possible. The timing of weaning and introduction of study formula will be left to the mother. The infants are randomized to be weaned to one of two study formulas: ( i) standard cow's milk formula and (ii) an extensively hydrolyzed casein formula. The target will be that the infant should be exposed to his/her study formula for at least 90 days before the age of 270 days. The diet of the infant will be studied with 3-day food records at the age of 3, 6, 9, and 12 months of age. To estimate the amount of breast milk received the weight of the infant will be measured just before and after each lactation. The HLA genotype will be analyzed from cord blood, and the result will be available within 10 days after birth. The family will visit the Study Center when the infant is 3, 6, 9, and 12-month-old. Blood samples will be obtained on each visit. In addition the families are asked to collect stool samples at home once a month during the study. Intestinal permeability will be assessed with the lactulose/mannitol test at the age of 3, 6, 9, and 12 months. Gut microflora will be analyzed with high-throughput, culture-independent methods and serum metabolome with established metabolomics platforms. Il-17 immunity will be studied using peripheral blood mononuclear cells. This work will generate novel knowledge of the disease process leading to overt T1D by studying potential mechanism(s) mediating the protective effect conferred by an extensively hydrolyzed casein formula against beta-cell autoimmunity. The identification of such mechanism(s) will most likely facilitate the refinement of effective preventive measures based on modifications of early infant nutrition.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: August 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 12 Months

Eligibility

Inclusion Criteria:

• The infant's parents give signed consent to participate and their HLA genotype is eligible.

Exclusion Criteria:

• An older sibling of the newborn infant has been included in this study;

• Multiple gestation;

• The parents are unwilling or unable to feed the infant cow's milk based products for any reason (e.g., religious, cultural);

• The gestational age of the newborn infant is less than 35 weeks

• Inability of the family to take part in the study (e.g. the family had no access to the Study Center or telephone)

• The newborn infant has a recognizable severe illness such as those due to chromosomal abnormality, congenital malformation, respiratory failure needing assisted ventilation, enzyme deficiencies, etc.;

• The infant receives any infant formula other than study formula or Nutramigen at the delivery hospital

• No HLA sample has been drawn before the age of 8 days.

Related Conditions & MeSH terms

• Autoimmune Diseases
• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Dietary Supplement:
• dietary intervention
hydrolyzed vs. nonhydrolyzed infant formula

Locations

Country	Name	City	State
Finland	Tampere University Hospital	Tampere

Sponsors (4)

Lead Sponsor	Collaborator
Helsinki University	National Institute for Health and Welfare, Finland, Tampere University Hospital, University of Turku

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Intestinal microbiome	The intestinal microbiome will be analyzed at the age of 3, 6, 9 , and 12 months	3, 6, 9 and 12 months
Primary	Intestinal permeability will be determined at the age of 3, 6, 9 and 12 months with the lactulose/mannitol test Intestinal permeability at the age of 9 months assessed with the lactulose/mannitol test	Intestinal permeability will be determined at the age of 3, 6, 9 and 12 months with the lactulose/mannitol test	3, 6, 9 and 12 months
Secondary	Serum metabolic profile	The serum metabolic profile wil be analyzed with metabolomics at the age of 3, 6, 9, and 12 months	3, 6, 9 and 12 months